

IN THE CLAIMS

Please amend the claims as follows:

Claims 1-8: (Canceled).

9. (Currently Amended): A method for alleviating a symptom from lipopolysaccharide-induced inflammation resulting from infection by bacteria which produce lipopolysaccharide, comprising ~~protectively~~ administering to a person orally or parenterally, prior to the infection by the bacteria, an effective amount of human-type lactoferrin for a time and under conditions effective to alleviate said symptom, wherein said symptom is accumulation of body fluid containing albumin at the inflammatory site.

10. (Previously Presented): The method according to claim 9, wherein the effective amount is 0.1 to 20 mg/kg of body weight/day in intravenous injection.

11. (Previously Presented): The method according to claim 10, wherein the effective amount is 0.5 to 10 mg/kg of body weight/day.

12. (Previously Presented): The method according to claim 9, wherein the effective amount is 1 to 200 mg/kg of body weight/day in intraperitoneal administration.

13. (Previously Presented): The method according to claim 9, wherein the effective amount is 5 to 1000 mg/kg of body weight/day in oral administration.

14. (Previously Presented): The method according to claim 13, wherein the effective amount is 20 to 1000 mg/kg of body weight/day.

15. (Currently Amended): A method for alleviating a symptom from lipopolysaccharide-induced inflammation resulting from infection by bacteria which produce lipopolysaccharide, comprising ~~protectively~~ administering to a person orally or parenterally, prior to the infection by the bacteria, an effective amount of human-type lactoferrin for a time and under conditions effective to alleviate said symptom, wherein said symptom is accumulation of albumin at the inflammatory site.

16. (Previously Presented): The method according to claim 15, wherein the effective amount is 0.1 to 20 mg/kg of body weight/day in intravenous injection.

17. (Previously Presented): The method according to claim 16, wherein the effective amount is 0.5 to 10 mg/kg of body weight/day.

18. (Previously Presented): The method according to claim 15, wherein the effective amount is 1 to 200 mg/kg of body weight/day in intraperitoneal administration.

19. (Previously Presented): The method according to claim 15, wherein the effective amount is 5 to 1000 mg/kg of body weight/day in oral administration.

20. (Previously Presented): The method according to claim 19, wherein the effective amount is 20 to 1000 mg/kg of body weight/day.

21. (Currently Amended): A method for alleviating a symptom from lipopolysaccharide-induced inflammation resulting from infection by bacteria which produce lipopolysaccharide, comprising ~~protectively~~ administering to a person orally or parenterally, prior to the infection by the bacteria, an effective amount of human-type lactoferrin for a time and under conditions effective to alleviate said symptom, wherein said symptom is decrease of albumin concentration in blood.

22. (Previously Presented): The method according to claim 21, wherein the effective amount is 0.1 to 20 mg/kg of body weight/day in intravenous injection.

23. (Previously Presented): The method according to claim 22, wherein the effective amount is 0.5 to 10 mg/kg of body weight/day.

24. (Previously Presented): The method according to claim 21, wherein the effective amount is 1 to 200 mg/kg of body weight/day in intraperitoneal administration.

25. (Previously Presented): The method according to claim 21, wherein the effective amount is 5 to 1000 mg/kg of body weight/day in oral administration.

26. (Previously Presented): The method according to claim 25, wherein the effective amount is 20 to 1000 mg/kg of body weight/day.

Claims 27-32: (Canceled).

33. (New) The method of Claim 9, wherein the lactoferrin is administered in the form of a tablet.

34. (New) The method of Claim 15, wherein the lactoferrin is administered in the form of a tablet.

35. (New) The method of Claim 21, wherein the lactoferrin is administered in the form of a tablet.

36. (New) The method of Claim 9, wherein the lactoferrin is administered parenterally.

37. (New) The method of Claim 15, wherein the lactoferrin is administered parenterally.

38. (New) The method of Claim 21, wherein the lactoferrin is administered parenterally.

39. (New) The method of Claim 9, wherein the lactoferrin is administered intravenously, intramucosally, percutaneously or intraperitoneally.

40. (New) The method of Claim 15, wherein the lactoferrin is administered intravenously, intramucosally, percutaneously or intraperitoneally.

41. (New) The method of Claim 21, wherein the lactoferrin is administered intravenously, intramucosally, percutaneously or intraperitoneally.